Financial Performance - Total operating revenue for the first three quarters of 2024 reached ¥407,336.18 million, an increase of 1.28% compared to ¥402,200.25 million in the same period last year[2] - Operating profit increased by 19.72% to ¥172,659.47 million from ¥144,224.99 million year-on-year[2] - Net profit attributable to shareholders of the listed company rose by 18.52% to ¥105,171.95 million, up from ¥88,740.04 million[2] - The basic earnings per share increased to ¥0.53, reflecting an 18.52% growth from ¥0.45[2] - The weighted average return on net assets improved to 10.27%, an increase of 0.67 percentage points from 9.60%[2] Assets and Equity - Total assets at the end of the reporting period were ¥1,555,362.07 million, a 9.62% increase from ¥1,418,805.69 million[2] - Shareholders' equity attributable to the listed company reached ¥1,064,125.90 million, up 8.33% from ¥982,257.92 million[2] - The number of shares outstanding increased by 20.00% to 197,737.14 million shares from 164,780.95 million shares[2] - The net asset per share attributable to shareholders decreased by 9.72% to ¥5.38 from ¥5.96[2] Revenue Drivers - The increase in sales revenue and profit margin was primarily driven by a rise in product sales prices year-on-year, contributing to an 18.52% increase in net profit attributable to shareholders[4]
天坛生物(600161) - 2024 Q3 - 季度业绩